Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Gilead Sciences stock last closed at $123.40, up 0.67% from the previous day, and has increased 34.58% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.25 percentage points. Gilead Sciences stock is currently +43.36% from its 52-week low of $86.08, and -0.97% from its 52-week high of $124.61.
There are currently 1.24B GILD shares outstanding. The market value of GILD is $153.12B. In the last 24 hours, 6.09M GILD shares were traded.
How to Buy Gilead Sciences Stock
Not sure how to invest in Gilead Sciences stock? Here's how.
Decide where to buy Gilead Sciences stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you decide where to buy Gilead Sciences stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit funds into your brokerage account: Choose your method of payment and add your details.
Analyze Gilead Sciences stock: The Gilead Sciences ticker symbol is GILD. Is Gilead Sciences stock a good investment? Should you buy shares of GILD? How do GILD's underlying business fundamentals look? Do top analysts think Gilead Sciences is a good buy? Why has GILD's stock price moved recently? (Hint: Our stock analysis website can help you figure out if GILD is a good stock to buy).
Execute your GILD purchase: Decide if you will purchase GILD shares at the current market price or use a limit order to buy GILD shares at a specific price.
Keep tabs on your investment in GILD: Create a watchlist to track your position in Gilead Sciences shares.
Step 1: Decide where to buy Gilead Sciences stock
You will need an online brokerage account to access the NASDAQ market and buy GILD stock.
A brokerage account is an investment account that enables you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
Invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to world markets: From Technology to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you can invest in GILD today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Gilead Sciences stock
After you have decided on the best place to buy Gilead Sciences stock, it's crucial to research their stock prior to buying, so you truly wrap your head around the risk and opportunity.
Gilead Sciences stock data
GILD Price
$123.40
1w %
4.19%
1y %
34.58%
5y %
108.9%
P/E
24.44x
P/B
7.78x
P/S
5.32x
PEG
1.05x
Revenue
$28.86B
Earnings
$6.31B
Fore. Rev. Growth
3.64%
Fore. Earn. Growth
23.25%
Market Cap
$153.12B
Next Earnings
N/A
Next Dividend
Dec 30, 2025
Gilead Sciences Overview
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
GILD's operating cash flow of $9.87B allows it to safely service it's debt of $24.95B.
GILD profit margin has gone up from 3.8% to 21.9% in the past year.
There are more short-term assets than short-term liabilities on the GILD balance sheet.
GILD earnings of $8.20B is not enough to cover its interest payments.
Total GILD debt is lower than 5 years ago, relative to shareholder equity.
Negative Health Checks:
There are more long-term liabilities than short-term assets on the GILD balance sheet.
GILD has a relatively high debt to equity ratio of 1.84.
Is it a good time to buy Gilead Sciences stock, according to analysts?
Out of 9 Wall Street analysts who monitor GILD, the consensus analyst rating on Gilead Sciences is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Latest GILD Analyst Forecasts
Joseph Stringer, a top 2% analyst from Needham reiterates GILD with a buy rating and maintains their GILD price target from $133.00 to $133.00, on Oct 31, 2025.
Tyler Van Buren, a bottom 4% analyst from TD Cowen maintains GILD with a strong buy rating and raises their GILD price target from $115.00 to $125.00, on Oct 23, 2025.
Geoff Meacham, a top 15% analyst from Citigroup maintains GILD with a strong buy rating and raises their GILD price target from $125.00 to $135.00, on Oct 8, 2025.
Citigroup's Geoff Meacham raised their price target on Gilead Sciences (NASDAQ: GILD) by 8% from $125 to $135 on 2025/10/08. The analyst maintained their Strong Buy rating on the stock.
Meacham attributed their price target hike on Gilead Sciences to data from Citigroup's survey of 100 physicians that indicated "strong initial trends for the Yeztugo launch in HIV.
Colin Bristow, a bottom 7% analyst from UBS maintains GILD with a hold rating and raises their GILD price target from $108.00 to $112.00, on Aug 8, 2025.
Last year, GILD earnings were $6.31B. In the past 4 year, GILD's earnings have increased by 5.22% per year. This was slower than the Drug Manufacturers - General industry average of 9.47%.
Last year, GILD revenue was $28.86B. In the past 5 year, GILD's revenue has gone up by 5.41% per year. This was slower than the Drug Manufacturers - General industry average of 10.82%.
Gilead Sciences pays a dividend of 2.54%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.19%. If you owned $1,000 worth of GILD stock, you would have been paid $25.45 last year.
Gilead Sciences dividend payments have consistently grown over the past decade and have remained stable.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your GILD purchase
There are two primary options:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are usually fine.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to make sure you're buying or selling at a given price, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you want additional assistance buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Gilead Sciences share?
As of Nov 6, 2025, it costs $123.40 to buy one share of Gilead Sciences stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.081 shares of GILD.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.